A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma

A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.

A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155

Inclusion Criteria:

• Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma
• Life expectancy >12 weeks

Exclusion Criteria:

• History of other malignancy in the last 5 years
• Major surgery within the past 21 days